Valuation: Xencor, Inc.

Market Cap 1.7B 1.51B 1.4B 1.27B 2.4B 161B 2.44B 16.83B 6.6B 84.14B 6.38B 6.24B 268B P/E 2026 *
-7.43x
P/E 2027 * -6.98x
Enterprise Value 1.27B 1.13B 1.04B 949M 1.79B 120B 1.82B 12.54B 4.92B 62.7B 4.75B 4.65B 200B EV / Sales 2026 *
8.84x
EV / Sales 2027 * 14x
Free-Float
98.78%
Yield 2026 *
-
Yield 2027 * -
1 day-4.79%
1 week-7.23%
Current month-8.42%
1 month-3.63%
3 months+52.84%
6 months+83.53%
Current year+49.25%
1 week 22.76
Extreme 22.76
25.32
1 month 22.56
Extreme 22.56
26.35
Current year 10.38
Extreme 10.375
30.61
1 year 10.38
Extreme 10.375
30.61
3 years 6.92
Extreme 6.92
30.61
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 31/01/2005
Director of Finance/CFO 48 08/04/2024
Chief Tech/Sci/R&D Officer 61 30/09/2006
Director TitleAgeSince
Director/Board Member 55 31/07/1997
Director/Board Member 58 24/07/2014
Director/Board Member 72 17/03/2015
Date Insider Type Main position Quantity % Market Cap. Importance
16/06/26 Free

Director

30,906 0.0417%
10/04/26 Sell

Chief Financial Officer

3,499 0.0048%
05/03/26 Sell

Chief Technology Officer

6,620 0.0090%
Change 5-day change 1-year change 3-year change Capi.($)
-4.79%-7.23%+52.84%+20.58% 1.7B
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -2.14%-2.22%+44.28%+79.19% 37.36B
Weighted average by Cap. -2.31%-1.23%+43.60%+88.27%

Financials

2026 *2027 *
Net sales 143M 127M 118M 107M 203M 13.59B 206M 1.42B 556M 7.09B 537M 526M 22.61B 122M 108M 100M 91.19M 172M 11.55B 175M 1.2B 472M 6.02B 457M 447M 19.21B
Net income -240M -213M -198M -180M -339M -22.75B -345M -2.37B -931M -11.87B -900M -881M -37.85B -287M -255M -236M -215M -406M -27.23B -412M -2.84B -1.11B -14.21B -1.08B -1.05B -45.29B
Net Debt -433M -385M -357M -325M -612M -41.09B -622M -4.29B -1.68B -21.44B -1.63B -1.59B -68.36B -
Projected Income Statement - Annual - Xencor, Inc.
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
16/10/26 US$22.85 -4.79% 1,129,982
15/10/26 US$24.00 +2.61% 726,920
14/10/26 US$23.39 -0.55% 1,369,922
13/10/26 US$23.52 -6.07% 2,425,957
12/10/26 US$25.04 +1.66% 753,049
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Xencor, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
22.85USD
Average target price
31.42USD
Spread / Average Target
+37.49%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Xencor, Inc.
  1. Stock Market
  2. Stocks
  3. XNCR Stock